Direct oral anticoagulants (DOACs) are essential for preventing blood clots in postoperative patients. However, their use in postpartum populations has been limited. This limitation exists because data on the transfer of these drugs into human milk is scarce. A new, recently published study specifically addresses the Rivaroxaban breastfeeding safety profile. It focuses on prophylactic doses in lactating individuals.
Researchers evaluated the excretion of prophylactic-dose rivaroxaban in 20 low-risk lactating participants. The individuals received two doses of the anticoagulant. Subsequently, they provided blood and milk samples. Quantifying the concentrations required liquid chromatography-tandem mass spectrometry.
Assessing Rivaroxaban Breastfeeding Safety via Relative Infant Dose
Pharmacokinetic metrics were a major focus of the study. Maternal plasma and milk rivaroxaban concentrations peaked simultaneously, approximately 2 hours after the second dose. The most crucial measurement for neonatal risk assessment is the relative infant dose (RID).
At the time of maximum maternal milk concentration of rivaroxaban, the calculated RID was 2.9%. Consequently, this is notably below the 10% safety threshold standard for drug use during lactation. Moreover, previous case studies focusing on higher therapeutic doses of rivaroxaban (15-30mg daily) reported RIDs in the 1.3% to 5% range. Thus, these findings consistently indicate that the drug’s transfer into human milk is minimal. Therefore, this robust new data suggests that neonatal exposure is likely low risk. This applies to mothers who require prophylactic-dose rivaroxaban for postpartum thromboprophylaxis.
Clinical Context: Anticoagulation in Postpartum Care
Anticoagulation is vital in the puerperium, which is the period of highest risk for venous thromboembolism (VTE). In India, guidelines have often favoured Low Molecular Weight Heparin (LMWH) or Warfarin for postpartum anticoagulation due to established safety profiles. Nevertheless, DOACs like rivaroxaban offer advantages such as oral administration and lack of routine monitoring. While current practice often contraindicates DOACs due toa lack of extensive data, the rising evidence base is notable. This new RID value may lead to changes in clinical guidelines. Therefore, doctors must consider this data. It helps in balancing VTE risk against the goal of successful breastfeeding.
Frequently Asked Questions
Q1: What was the key finding regarding the transfer of prophylactic rivaroxaban into human milk?
The study determined that the relative infant dose (RID) of rivaroxaban was 2.9% at the maximum maternal milk concentration.
Q2: What is the established safety threshold for relative infant dose (RID)?
The established safety threshold for drug use during breastfeeding is a relative infant dose of 10%.
Q3: Does this new data change the risk assessment for neonatal exposure?
The findings indicate that neonatal exposure is likely low risk when prophylactic-dose rivaroxaban is used in lactating individuals.
References
- Bruno AM et al. Prophylactic-Dose Rivaroxaban Transfer Into Human Milk. Obstet Gynecol. 2025 Dec 18. doi: 10.1097/AOG.0000000000006153. PMID: 41411660.
- Rivaroxaban. Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006–.
- Beyer G, et al. Rivaroxaban Treatment in Two Breastfeeding Mothers: A Case Series. Breastfeed Med. 2020 Jan;15(1):41-43.